Ewing sarcoma family of tumors in children younger than 10 years of age

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26275. Epub 2016 Oct 3.

Abstract

Aim: Few data exist regarding the clinical characteristics and outcome of young children with Ewing sarcoma family of tumors (ESFT).

Methods: We reviewed the records of ESFT patients at our institution younger than 10 years of age at diagnosis.

Results: Forty-two patients were identified. Median age was 6.4 years (range 0.6-9.5 years). Most patients had T2 (>5 cm) tumors (n = 31; 74%). Most common primary site was the extremity (n = 17; 41%). Seven patients (17%) had metastasis at diagnosis. For local tumor control, 20 patients had surgery only, 13 had radiation therapy only, and 6 had surgery plus radiation. Surgical margin status was negative in 19 patients (73%). Median follow-up was 4.7 years (range 0.7-29.7 years), and 5-year relapse-free survival (RFS) and overall survival (OS) estimates were 67% (95% CI: 53-84%) and 82% (95% CI: 71-95%), respectively. Metastasis at presentation was the only significant predictor for decreased RFS (P = 0.008) and OS (P = 0.01). A trend was seen for T2 tumors with worse OS (P = 0.09).

Conclusion: Patients younger than 10 years of age with ESFT may have a better OS than older patients, but further study of a homogeneously treated larger cohort is needed.

Keywords: Ewing sarcoma; bone; childhood cancer; pediatric; sarcoma; solid tumor.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Newborn
  • Lymphatic Metastasis
  • Male
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Sarcoma, Ewing / pathology
  • Sarcoma, Ewing / therapy*
  • Survival Rate